Product Specialists are available
Mon-Fri 9am-5pm MST
Call or Text:
Dallin from the Hardy Nutritionals® science team shares an ADHD research update on Hardy's Daily Essential Nutrients, a clinical micronutrient therapy designed to alleviate mood and mental health symptoms.
In 2019, a study titled "Mineral-Vitamin Treatment Associated with Remission in Attention-Deficit/Hyperactivity Disorder Symptoms and Related Problems: 1-Year Naturalitic Outcomes of a 10-Week Randomized Placebo-Controlled Trial" was published in The Journal of Child and Adolescent Psychopharmacology. This study was a follow-up to the original study which was published in The Journal of Child Psychology and Psychiatry in 2017 titled "Vitamin-mineral treatment improves aggression and emotional regulation in children with ADHD: a fully blinded, randomized, placebo-contnrolled trial".
The vitamin-mineral treatment studied is Daily Essential Nutrients, formulated by Hardy Nutritionals®.
The original trial is a landmark study for ADHD, the first of its kind. The research demonstrated significant improvements in the children's symptoms in both the original study and the one-year follow up trial. While Daily Essential Nutrients is clinically validated for use across a wide range of mood and mental health disorders for both children and adults, this new research focuses specifically on children with ADHD.
So first of all, what is a Randomized Double-Blind Placebo-Controlled Trial?
A Randomized Double-Blind Placebo-Controlled Trial, or RDBPCT, is "a medical study involving human participants in which neither side knows who's getting what treatment and placebo are given to a control group". Therefore, participants were given either the Daily Essential Nutrients or placebo, without knowing which they were receiving. In addition, the researchers also were "blinded" to which capsules the study participants were getting. However, those who did not receive the micronutrients during the initial 10-week trial period, were able to try the micronutrients for 10-weeks after their placebo trial. At the conclusion of the 20-week period, researchers made a final assessment of each participant and took a look at the data to make some conclusions. One year later, the researchers followed-up again to see what the outcomes were long-term.